MGO One Seven LLC Acquires 9,168 Shares of Bristol Myers Squibb Company $BMY

MGO One Seven LLC lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 27.2% during the 4th quarter, Holdings Channel reports. The firm owned 42,815 shares of the biopharmaceutical company’s stock after purchasing an additional 9,168 shares during the quarter. MGO One Seven LLC’s holdings in Bristol Myers Squibb were worth $2,309,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares in the last quarter. State Street Corp boosted its position in shares of Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Bristol Myers Squibb by 11.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock valued at $818,105,000 after purchasing an additional 1,873,618 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Bristol Myers Squibb by 8.4% during the 3rd quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock valued at $770,116,000 after purchasing an additional 1,317,199 shares in the last quarter. Finally, Pzena Investment Management LLC boosted its position in shares of Bristol Myers Squibb by 0.4% during the 3rd quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company’s stock valued at $672,062,000 after purchasing an additional 58,129 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.1%

BMY stock opened at $56.10 on Monday. The stock’s 50 day simple moving average is $59.28 and its 200 day simple moving average is $54.91. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market cap of $114.56 billion, a P/E ratio of 15.76, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.3 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Wells Fargo & Company restated an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $61.31.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.